This observational study aims to improve how we predict acute kidney injury (AKI), a sudden decrease in kidney function, in hospitalized patients. Researchers are looking at whether adding information from blood and urine tests (biomarkers) can make a special computer program called ESTOP - AKI 2.0 even better at identifying patients at high risk for severe AKI. The ESTOP - AKI 2.0 program uses information from your electronic health records. The study will enroll 800 adults who are already identified as high-risk by the ESTOP - AKI 2.0 program. The main goal is to see if combining these biomarkers with the electronic risk score can more accurately predict if you will develop Stage 2 AKI within 7 days of joining the study. The current recruitment status is unclear.

Study design

This is an observational study planning to enroll 800 participants. It aims to see if adding biomarkers improves the prediction of AKI when combined with an electronic risk score.

What's involved

If you join, blood and urine samples will be collected over the next 3 days after you are identified as high-risk.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint for developing KDIGO stage 2 AKI is measured within 7 days of enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.